Percheron Therapeutics Limited (ASX:PER)
Australia · Delayed Price · Currency is AUD 0.0050
-0.0005 (-9.09%)
Aug 21, 2026, 2:58 PM AEST
Percheron Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 4.05 | 10.17 | 11.87 | 10.97 | 19.23 |
Cash & Short-Term Investments | 4.05 | 10.17 | 11.87 | 10.97 | 19.23 |
Cash Growth | -60.15% | -14.32% | 8.20% | -42.98% | 219.47% |
Accounts Receivable | 0.96 | 0.06 | 0.08 | 0.03 | 0.03 |
Other Receivables | - | 1.52 | 2.48 | 1.63 | 1.81 |
Receivables | 0.96 | 1.58 | 2.57 | 1.66 | 1.84 |
Prepaid Expenses | 0.27 | 0.65 | 0.04 | 0.07 | 0.61 |
Other Current Assets | - | - | - | - | 0.53 |
Total Current Assets | 5.29 | 12.4 | 14.47 | 12.69 | 22.22 |
Property, Plant & Equipment | 0.04 | 0.04 | 0.06 | 0.15 | 0.22 |
Other Intangible Assets | 2.9 | - | - | - | - |
Total Assets | 8.22 | 12.44 | 14.53 | 12.84 | 22.44 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 0.49 | 1.43 | 3.73 | 1.02 | 0.33 |
Accrued Expenses | 0.17 | 0.16 | 0.25 | 1.69 | 0.73 |
Current Portion of Leases | 0.03 | 0.03 | 0.04 | 0.09 | 0.09 |
Other Current Liabilities | - | 0.81 | 1.14 | 0 | 0 |
Total Current Liabilities | 0.69 | 2.43 | 5.15 | 2.81 | 1.16 |
Long-Term Leases | - | - | - | 0.05 | 0.13 |
Other Long-Term Liabilities | - | - | 0.02 | 0.01 | 0 |
Total Liabilities | 0.69 | 2.43 | 5.17 | 2.87 | 1.3 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 63.42 | 112.05 | 109.37 | 98.26 | 98.13 |
Retained Earnings | -57.97 | -103.67 | -101.73 | -92.29 | -80.91 |
Comprehensive Income & Other | 2.08 | 1.62 | 1.72 | 4 | 3.92 |
Shareholders' Equity | 7.53 | 10 | 9.36 | 9.98 | 21.14 |
Total Liabilities & Equity | 8.22 | 12.44 | 14.53 | 12.84 | 22.44 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 0.03 | 0.03 | 0.04 | 0.14 | 0.23 |
Net Cash (Debt) | 4.02 | 10.14 | 11.83 | 10.83 | 19.01 |
Net Cash Growth | -60.32% | -14.25% | 9.25% | -43.04% | 232.64% |
Net Cash Per Share | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 |
Filing Date Shares Outstanding | 1,250 | 1,087 | 901.54 | 836.3 | 668.79 |
Total Common Shares Outstanding | 1,250 | 1,087 | 901.54 | 669.31 | 668.79 |
Working Capital | 4.59 | 9.97 | 9.32 | 9.88 | 21.06 |
Book Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 |
Tangible Book Value | 4.63 | 10 | 9.36 | 9.98 | 21.14 |
Tangible Book Value Per Share | 0.00 | 0.01 | 0.01 | 0.01 | 0.03 |